Selected nutraceutic screening by therapeutic effects on doxorubicin-induced chronic kidney disease

Chiung Chi Peng, Chiu Lan Hsieh, Yaw Bee Ker, Hsi Yi Wang, Kuan Chou Chen, Robert Y. Peng

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Scope: The number of patients with chronic kidney disease (CKD) are increasing. Interventions such as controlling hypertension and specific pharmacologic options are recommended. Some nutraceutics may have benefits in this regard. Methods and results: Naringenin (a flavanon), catechin (a flavanol), and quercetin (a flavonol) and rutin (a flavonol rutinoside) were tried on CKD in a Sprague Dawley rat model. Results indicated quercetin to be the most effective therapeutic candidate with respect to renal edema, hypertension, serum creatinine, hematocrit, cardiopathy, aorta calcification, glomerular amyloidosis, erythrocyte depletion in bone marrow, collagen deposition, expressions of TNF-α, cleaved caspase-3, IκBα, PPARα, and serum insulin. But quercetin was only partially effective in restoring glomerular filtration rate, albuminuria, serum cholesterol, triglyceride, blood urea nitrogen (BUN), uric acid, malondialdehyde, superoxide dismutase; urinary BUN and urinary creatinine. As for signaling, quercetin was completely effective in alleviating the cleaved caspase-3, being only partially effective in suppressing Bax and Bad, restoring Bcl-2, and rescuing DNA damage. Conclusion: The CKD status cannot to be ameliorated by naringenin, rutin, and catechin. Comparatively, quercetin may be a better therapeutic candidate.

Original languageEnglish
Pages (from-to)1541-1558
Number of pages18
JournalMolecular Nutrition and Food Research
Volume56
Issue number10
DOIs
Publication statusPublished - Oct 2012

Keywords

  • Apoptosis
  • Chronic kidney disease
  • Cytokines
  • Hyperlipidemia
  • Quercetin

ASJC Scopus subject areas

  • Biotechnology
  • Food Science

Fingerprint

Dive into the research topics of 'Selected nutraceutic screening by therapeutic effects on doxorubicin-induced chronic kidney disease'. Together they form a unique fingerprint.

Cite this